Eli Lilly
VC Fund
Indianapolis, United States
Eli Lilly is a VC fund in Indianapolis focused on Biotechnology and Health Care. Eli Lilly engages in the discovery, development, manufacture, and sale of products in the pharmaceutical products business segment. The company manufactures and distributes products through owned or leased facilities in the United States, Puerto Rico, and 25 other countries. Its products are sold in approximately 135 countries. It also conductsresearch to find products to treat diseases in animals and to increase the efficiency of animal food production.
- Total investments:
- 152
- Last investment:
- Lead investor:
- 23%
Last updated:
For AI agents: llms.txt
Industries Eli Lilly invests in
Stages Eli Lilly invests in
Countries Eli Lilly invests in
Round sizes
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
| See all 14 contacts → | |||
Round size
- Series A
- $7M–$94M
- Series B
- $11M–$150M
- Series C
- $11M–$107M
Investment Focus
Industry
- Biotechnology 96 (63%)
- Health Care 56 (37%)
- Medical 41 (27%)
- Therapeutics 34 (22%)
- Pharmaceutical 33 (22%)
Stage
- Series A 46 (30%)
- Series B 34 (22%)
- Series C 14 (9%)
- Venture - Series Unknown 12 (8%)
- Corporate Round 11 (7%)
Country
- United States 92 (61%)
- United Kingdom 12 (8%)
- Canada 4 (3%)
- China 2 (1%)
- France 2 (1%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
Barton Peterson
Senior Vice President, Corporate Affairs & Communications
|
Senior Vice President, Corporate Affairs & Communications | Total investments: 0 | Find email | |
|
Bill Ringo
President
|
President | Total investments: 0 | Find email | |
Daniel Skovronsky
Senior Vice President, and Chief Scientific Officer
|
Senior Vice President, and Chief Scientific Officer | Total investments: 0 | Find email | |
Dr Eddie Guzdar
Senior Medical Director - Immunology Northern Europe
|
Senior Medical Director - Immunology Northern Europe | Total investments: 0 | Find email | |
Eric Dozier
SVP, Human Resources, and Diversity
|
SVP, Human Resources, and Diversity | Total investments: 0 | Find email | |
| See all 14 team members → | ||||
Investments
| Company | Description | Round | Links |
|---|---|---|---|
| BigHat is a developer of an AI-guided protein therapeutic platform used to integrate antibody characterization lab with machine learning technologies to engineer molecules with more complex functions and better biophysical properties. The company is applying these design capabilities to develop new generations of safer and more effective treatmentsfor patients suffering from today’s most challenging diseases. | $75M / Series C / Sep 24, 2026 | ||
| Circle Pharma is an early-stage biotechnology company applying proprietary computational design algorithms and innovative chemistry to develop cell-permeable macrocycle peptide therapeutics against important clinical targets. It does this through an iterative, rational design process that deploys large virtual libraries of conformationally diversemacrocycle scaffolds selected for inherent permeability. The company was founded by Matt Jacobson and Scott Lokey in 2012 and is headed by David J. Earp. | $92.5M / Series E / Sep 16, 2026 | ||
| Thatch helps businesses give great healthcare to their employees. | $108M / Series C / Sep 15, 2026 | ||
| Nanology Labs has designed and is developing Manganescan®, a novel theranostic agent (MRI contrast agent/Radio-sensitizer) that allows detection of brain tumors at early stages using MRI. Simultaneously, it sensitizes cancer cells which improves radiation therapy outcomes. The agent is 3x more sensitive than current Gadolinium contrast agents(GBCAs), can cross the blood brain barrier and enables early and precise detection and targeting of brain cancer. | Corporate Round / Sep 15, 2026 | ||
| Caspian Therapeutics is advancing a portfolio of small-molecule menin inhibitors, including its lead asset KO-7246, as potential disease-modifying treatments for diabetes and chronic metabolic conditions. The company's therapeutic approach focuses on restoring the body's natural insulin production capacity through selective expansion andenhanced function of pancreatic β cells. Supported by a syndicated investor base, its model centers on transforming standard clinical paradigms from symptom management to cell-level regeneration. | $50M / Seed / Sep 09, 2026 | ||
| Moonwalk Biosciences is a genomic medicine startup that aims to provide a new class of precision epigenetic therapeutics. The company is working on the development of a profiling and engineering technology platform that, with the help of advanced artificial intelligence prediction, provides a comprehensive view of the epigenome in health anddisease, allowing healthcare providers to take a fresh look at how therapies are discovered and developed. | $70M / Series B / Sep 08, 2026 | ||
| Cloverleaf Bio develops an RNA therapeutic platform for oncology. | $33M / Seed / Sep 08, 2026 | ||
| Superluminal Medicines is a generative biological and chemical company accelerating new possibilities in drug discovery and development. Its platform creates candidate-ready compounds with speed using a comprehensive combination of deep biology and chemistry expertise, machine learning, and proprietary big data infrastructure. | $65.5M / Series B / Sep 03, 2026 | ||
| Leal Therapeutics develops novel therapeutics for patients. | $30M / Series A / Aug 17, 2026 | ||
| Amplifica is a preclinical stage biopharmaceutical company focused on developing novel treatments to address androgenic alopecia. | $26M / Series B / Aug 12, 2026 | ||
| See all 152 investments → | |||
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar stage
Similar country
Featured in Investor Lists
Recommended lists
FAQ
What does Eli Lilly invest in?
Eli Lilly invests primarily in Biotechnology, Health Care and Medical startups, most often at Series A and Series B stage. Most of the 152 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What is Eli Lilly's check size?
Eli Lilly typically joins rounds of $7M–$94M at Series A, $11M–$150M at Series B and $11M–$107M at Series C. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds Eli Lilly participates in.
How do I contact Eli Lilly?
Public channels for Eli Lilly include LinkedIn, X (Twitter) and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at Eli Lilly?
The team at Eli Lilly includes Barton Peterson (Senior Vice President, Corporate Affairs & Communications), Bill Ringo (President) and Daniel Skovronsky (Senior Vice President, and Chief Scientific Officer), among 14 team members tracked by Shizune. The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Oct 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
